Equity Brief · Healthcare2026-05-20
AMGN·Healthcare

Amgen Inc

I · Analyse IA

En bref

Amgen discovers, develops, manufactures, and delivers prescription medicines for serious illnesses including rheumatoid arthritis (Enbrel), high cholesterol (Repatha), osteoporosis (Prolia, Evenity), cancer (Blincyto, Kyprolis, Vectibix), and rare diseases like thyroid eye disease (Tepezza) [Yahoo Finance]. The company sells through doctors' offices, hospitals, dialysis centers, and pharmacies, primarily via pharmaceutical wholesalers [Yahoo Finance].

Amgen is the world's largest independent biotech company, developing and selling medicines for cancer, autoimmune diseases, osteoporosis, and rare conditions [Yahoo Finance]. The company generates $36.7B in annual revenue with strong margins, but faces serious safety concerns around its drug Tavneos, which has been linked to 20 deaths and 22 liver injuries in Japan [Seeking Alpha]. Recent leadership changes include the retirement of CFO Peter Griffith, who will be replaced by returning veteran Thomas Dittrich [Yahoo Finance].

Amgen is financially healthy with strong cash generation and reasonable leverage, earning a 7.4/10 health score [Yahoo Finance].

En bref AI analysisConfiance 8/10

Score Sentinellis

7.4/10

Financially healthy

Capitalisation boursière

$178.6B

Chiffre d'affaires (12 mois)

$36.7B

II · Actualités récentes

Ce qui a fait bouger le cours

6 stories · ranked by relevance

  • macro2026-05-19

    AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

    Yahoo Finance

  • macro2026-05-18

    Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism

    Yahoo Finance

  • macro2026-05-18

    Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed

    Yahoo Finance

  • macro2026-05-18

    Amgen Japanese Partner Urges Caution On Tavneos Use

    Yahoo Finance

  • macro2026-05-15

    Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains

    Simply Wall St

  • macro2026-05-15

    Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

    Zacks

Premium · gratuit avec tout compte

Tavneos faces serious safety scrutiny in Japan after being linked to 20 deaths and 22 liver injuries, which could lead to restricted use, regulatory action, or lawsuits in other markets where Amgen sells the drug [Seeking Alpha]

1 sur 4 risques dans ce rapport

Risques

4

Opportunités

5

Signaux d'alerte

3

Direction

10

21 autres constats dans le rapport complet — gratuit avec tout compte.

Débloquer l'analyse complète de Amgen Inc

Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.

  • 4 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
  • Plus de 100 indicateurs financiers avec graphiques et comparaisons
  • Résumés d'actualités complets avec liens vers les sources
  • Équipe dirigeante et rémunération
  • Export PDF pour la lecture hors ligne
Débloquer les 12 constats3 rapports gratuits · sans carte

III · Entreprises similaires

À lire également

Same sector · Healthcare or comparable health

L'ajouter à votre liste ?

Read three companies free. Sans carte.

Obtenir 3 rapports gratuits